Previous 10 | Next 10 |
home / stock / lbtsf / lbtsf news
Almirall, S.A. (LBTSF) Q1 2020 Earnings Conference Call May 11, 2020 04:00 AM ET Company Participants Pablo Divasson del Fraile - Chief Investor Relations and Corporate Communications Peter Guenter - CEO Mike McClellan - EVP and CFO Amita Kent - General Counsel Bhushan Hardas...
Almirall, S.A. (LBTSF) Q4 2019 Results Earnings Conference Call February 24, 2020, 04:00 AM ET Company Participants Pablo Divasson del Fraile - Chief Investor Relations and Corporate Communications Peter Guenter - Chief Executive Officer Bhushan Hardas - Executive Vice President...
The following slide deck was published by Almirall, S.A. in conjunction with their 2019 Q4 earnings Read more ...
Almirall, S.A. ( OTC:LBTSF ): Q4 net income of €136.1M Revenue of €908.4M (+12.0% Y/Y) Press Release More news on: Almirall, S.A., Earnings news and commentary, Healthcare stocks news,
Almirall S.A. ( OTC:LBTSF ) is starting the new year with a flurry of deals. More news on: Almirall, S.A., Wuxi Biologics (Cayman) Inc ADR, WuXi Biologics (Cayman) Inc., Healthcare stocks news, Read more ...
Almirall, S.A. (LBTSF) Q3 2019 Earnings Conference Call November 11, 2019 4:00 AM ET Company Participants Pablo Divasson del Fraile – Chief Investor Relations and Corporate Communications Peter Guenter – Chief Executive Officer Bhushan Hardas – Executive Vice...
The following slide deck was published by Almirall, S.A. in conjunction with their 2019 Q3 earnings Read more ...
Almirall, S.A. ( OTC:LBTSF ): 9M net income of €97.3M More news on: Almirall, S.A., Earnings news and commentary, Healthcare stocks news, Read more ...
Quick Take Cabaletta Bio ( CABA ) has filed to raise $87 million in an IPO of its common stock, according to an S-1/A registration statement . The firm is developing drug treatments for Pemphigus and other autoimmune conditions. CABA is an ultra-high-risk pre-Phase 1 stage biopharma, an...
Dosing is underway in a Phase 3 clinical trial evaluating Dermira's (NASDAQ: DERM ) lebrikizumab, an IL-13 inhibitor, in patients at least 12 years old with moderate-to-severe atopic dermatitis (AD). More news on: Dermira, Inc., Almirall, S.A., Healthcare stocks news, Stocks on the move...
News, Short Squeeze, Breakout and More Instantly...
Almirall Sa Ord Company Name:
LBTSF Stock Symbol:
OTCMKTS Market:
Strong growth trajectory maintained with Net Sales increase of 6.7% to a total of €497.2 MM, EBITDA of €104.5 MM (+3.2% YoY) driven by increased overall sales and strong performance of biologics portfolio Biologics continue to be key growth engines for Almirall: Ebglyss ...
Lebrikizumab is recommended by NICE for the use in moderate to severe Atopic Dermatitis in patients 12 years and over when their condition has not responded to at least 1 systemic immunosuppressant, or when these treatments are not suitable Following approval of the European Commission (Octob...
Almirall’s sustainability strategy focuses on five pillars: Planet, People, Patients, Partners and Principles defining clear targets and measurements Among other commitments, Almirall aims to – by 2030 - reduce absolute direct greenhouse gas emissions by 50%, minimize the ge...